New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 9, 2013
09:20 EDTCOV, ESS, HEB, GIVN, BRE, GILD, SYY, NIHD, EWOn The Fly: Pre-market Movers
HIGHER: Sysco (SYY), up 26% after buying privately-held US Foods in deal with total enterprise value $8.2B... Given Imaging (GIVN), up 25% after agrees to be acquired by Covidien (COV) for $30 per share... Hologic (HOLX), up 3% after appointing two directors pursuant to settlement agreement with Icahn... Gilead (GILD), up 4% after FDA approves chronic hepatitis C treatment, company reports results from Phase 2 study evaluating GS-9973... Hemispherx Biopharma (HEB), up 32% after FDA authorizes expansion of Ampligen/FluMist intranasal clinical trial. LOWER: NII Holdings (NIHD), down 10% after announcing restructuring plan that will reduce staff... Edwards Lifesciences (EW), down 5% after reaffirming FY13 guidance, issuing FY14 outlook... BRE Properties (BRE), down 2% after Essex Property Trust (ESS) confirms offer to acquire BRE for for 0.2971 shares of Essex common stock and $12.33 in cash.
News For SYY;GIVN;COV;GILD;HEB;EW;BRE;ESS;NIHD From The Last 14 Days
Check below for free stories on SYY;GIVN;COV;GILD;HEB;EW;BRE;ESS;NIHD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
April 14, 2014
09:36 EDTGILDActive equity options trading on open
Subscribe for More Information
09:09 EDTGILDGilead poised to be leader in all-oral HCV treatment, says Wells Fargo
After attending the EASL conference, Wells Fargo believes that Gilead's HCV treatment has multiple advantages over the competition. The firm keeps an Outperform rating on the stock.
09:00 EDTEWEdwards Lifesciences rises 11.3%
Edwards Lifesciences is up 11.3%, or $8.28, to $81.25
08:59 EDTEWOn The Fly: Pre-market Movers
Subscribe for More Information
08:15 EDTGILDBristol-Myers submits NDA for Reyataz-cobicistat combo for HIV-1
Bristol-Myers Squibb (BMY) announced the submission of a new drug application, or NDA, on April 4 to the FDA for a fixed-dose combination of atazanavir sulfate, a protease inhibitor marketed as Reyataz, and cobicistat, an investigational pharmacokinetic enhancer, or boosting agent, that can increase the level of certain HIV-1 medicines in the blood and make them more effective. Bristol-Myers Squibb is seeking approval of the fixed-dose combination tablet for use in combination with other antiretroviral agents for the treatment of HIV-1 infection. If approved, atazanavir sulfate and cobicistat could offer patients living with HIV-1 a single tablet that eliminates the need to take a boosting agent in a separate tablet. Cobicistat is being developed by Gilead Sciences (GILD). Under the terms of a previously announced agreement, Bristol-Myers Squibb and its affiliates are responsible for the formulation, manufacturing, registration, distribution and commercialization of the atazanavir sulfate and cobicistat fixed-dose combination product worldwide. Gilead retains sole rights for the manufacture, development and commercialization of cobicistat as a stand-alone product and for use in combination with other agents.
08:12 EDTEWEdwards Lifesciences price target raised to $90-$91 from $82-$83 at Wells Fargo
Wells Fargo increased its price target on Edwards after a federal court granted a preliminary injunction limiting the sale of a competing product, Medtronic's (MDT) CoreValve. The firm said the injunction was a "major surprise," and estimates that the injunction could increase Edwards EPS by 15c in 2014 and 34c in 2015. Wells keeps an Outperform rating on the stock.
08:05 EDTCOVCovidien announces FDA 510(k) clearance for Kangaroo feeding tube
Subscribe for More Information
07:59 EDTGILDGilead Sovaldi should take majority share of HCV market, says Stifel
Subscribe for More Information
07:45 EDTGILDAbbVie defended at BMO Capital
Subscribe for More Information
07:39 EDTEWEdwards Lifesciences upgraded to Buy from Fair Value at CRT Capital
Subscribe for More Information
06:22 EDTEWMedtronic downgraded to Neutral from Overweight at JPMorgan
Subscribe for More Information
06:21 EDTEWEdwards Lifesciences upgraded to Neutral from Underweight at JPMorgan
Subscribe for More Information
April 13, 2014
15:10 EDTEWMedtronic says CoreValve ruling has no impact outside U.S.
Subscribe for More Information
April 12, 2014
19:50 EDTEWEdwards says court limits sale of Medtronic CoreValve system in U.S.
Edwards Lifesciences (EW) announced that the U.S. District Court for the District of Delaware granted a preliminary injunction limiting the sale of Medtronic's (MDT) CoreValve system in the United States. The court ordered the injunction to go into effect in seven business days. The hearing related to a federal jury decision in 2010 that CoreValve willfully infringes Edwards' U.S. Andersen transcatheter aortic valve replacement patent. At the conclusion of the hearing, Chief Judge Gregory Sleet ordered Edwards and Medtronic to confer on what instances the CoreValve device could continue to be used in the treatment of U.S. patients at centers currently trained on CoreValve. There is a large body of evidence demonstrating the safety and performance of the Edwards SAPIEN valves, and the company remains committed to ensuring patients have appropriate access to transcatheter therapy. This case was initiated by Edwards in 2008. On April 1, 2010, a federal jury found Medtronic willfully infringed Edwards' U.S. Andersen patent and awarded damages. In Nov. 2012, the U.S. Court of Appeals for the Federal Circuit affirmed the jury decision; in Oct. 2013, the U.S. Supreme Court declined to hear Medtronic's appeal. The patent involved in this suit is part of the Andersen family of patents. The U.S. Andersen patent was issued in 1995. A petition has been filed with the U.S. Patent and Trademark Office to extend this patent into early 2016. In a separate case, a federal jury in January found that Medtronic CoreValve had willfully infringed Edwards' U.S. Cribier transcatheter heart valve patent, and awarded damages to Edwards in that trial.
April 11, 2014
12:04 EDTGILDStocks with call strike movement; AMZN GILD
Amazon.com (AMZN) May 380 call option implied volatility decreased 3% to 43, Gilead (GILD) August 77 call option implied volatility decreased 15% to 45 according to IVolatility.
11:42 EDTCOVCovidien liability from recall appears limited, says Brean Capital
Subscribe for More Information
09:37 EDTGILDActive equity options trading on open
Subscribe for More Information
08:58 EDTGILDGilead valuation attractive at current levels, says RBC Capital
Subscribe for More Information
08:10 EDTCOVCovidien implements voluntary recall of devices
Subscribe for More Information
05:25 EDTGILDGilead announces 95% virologic suppression in HCV study
Gilead Sciences announced data from two Phase 2 studies and a compassionate access study in which a regimen containing once-daily Sovaldi 400 mg was administered for the treatment of chronic hepatitis C virus infection in patients with advanced liver disease. The first study, Study GS-US-334-0125, is an ongoing open-label Phase 2 clinical trial evaluating HCV patients with cirrhosis and portal hypertension, with or without decompensation, who were randomized 1:1 to an immediate treatment arm in which Sovaldi and ribavirin was administered for 48 weeks or to a deferred treatment arm in which this regimen was initiated after a 24-week observation period. Eighty percent of participants were treatment-experienced. Of the 22 patients who completed 24 weeks of therapy, 95% achieved virologic suppression on treatment. Additionally, patients taking Sovaldi-based therapy experienced trends in clinical and laboratory parameter improvements compared to patients in the observation arm. Sovaldi-based therapy was well tolerated in the study, and only one patient discontinued treatment due to an adverse event. The most common adverse events occurring in more than 25 percent of patients included nausea and pruritis.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use